Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 17/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 16/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8295721 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1363636 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1366029 | 0.99 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1364916 | 0.95 | HDAC1 (0.92) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL12727095 | 0.90 | HDAC1 (0.81) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL12727094 | 0.88 | HDAC1 (0.81) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1366003 | 0.87 | HDAC1 (0.77) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL13784484 | 0.86 | HDAC1 (0.85) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL16573398 | 0.85 | HDAC1 (0.76) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL4308807 | 0.85 | HDAC1 (0.85) | HDAC1HDAC2HDAC10HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644323-B1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-1644323-B1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2258677-B1 | HISTONE DEACETYLASE INHIBITORS | UNIV GEORGETOWN (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8748463-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748463-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065963-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065963-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8222451-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222451-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8067600-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090163543-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | US | disclosed |
| US-7507828-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507828-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507828-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1644323-A4 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1644323-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032831-A1 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY | 2005-02-10 | — | — | US | disclosed |
| WO-2005007091-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007091-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065963-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC6, HDAC1 | HDAC1 3/4885HDAC2 8/4885HDAC10 11/4885 |
| US-20090163543-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC6, HDAC1 | HDAC1 3/4885HDAC2 5/4885HDAC10 11/4885 |
| US-20050032831-A1 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC6, HDAC1 | HDAC1 3/4885HDAC2 5/4885HDAC10 11/4885 |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC6, HDAC1 | HDAC1 3/4885HDAC2 8/4885HDAC10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.